TWI318214B - Somatosatin-dopamine chimeric analogs - Google Patents

Somatosatin-dopamine chimeric analogs

Info

Publication number
TWI318214B
TWI318214B TW091112381A TW91112381A TWI318214B TW I318214 B TWI318214 B TW I318214B TW 091112381 A TW091112381 A TW 091112381A TW 91112381 A TW91112381 A TW 91112381A TW I318214 B TWI318214 B TW I318214B
Authority
TW
Taiwan
Prior art keywords
somatosatin
dopamine chimeric
chimeric analogs
analogs
dopamine
Prior art date
Application number
TW091112381A
Other languages
English (en)
Inventor
D Culler Michael
Xin Dong Zheng
H Kim Sun
Moreau Jacques-Pierre
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Application granted granted Critical
Publication of TWI318214B publication Critical patent/TWI318214B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/02—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hydrocarbon or substituted hydrocarbon radicals, attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/10—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hetero atoms directly attached in position 8
    • C07D457/12—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
TW091112381A 2001-06-08 2002-06-07 Somatosatin-dopamine chimeric analogs TWI318214B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29705901P 2001-06-08 2001-06-08

Publications (1)

Publication Number Publication Date
TWI318214B true TWI318214B (en) 2009-12-11

Family

ID=23144680

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091112381A TWI318214B (en) 2001-06-08 2002-06-07 Somatosatin-dopamine chimeric analogs

Country Status (25)

Country Link
US (4) US7579435B2 (zh)
EP (2) EP1401863B1 (zh)
JP (2) JP3996897B2 (zh)
KR (3) KR100743212B1 (zh)
CN (2) CN1514843A (zh)
AR (1) AR037226A1 (zh)
AT (1) ATE424414T1 (zh)
AU (1) AU2002305845B2 (zh)
BR (1) BR0210915A (zh)
CA (1) CA2449634C (zh)
CZ (1) CZ305160B6 (zh)
DE (1) DE60231403D1 (zh)
DK (2) DK1401863T3 (zh)
ES (2) ES2483722T3 (zh)
HK (1) HK1060360A1 (zh)
HU (1) HUP0400245A3 (zh)
IL (2) IL158922A0 (zh)
MX (1) MXPA03011321A (zh)
NO (2) NO332042B1 (zh)
NZ (1) NZ530007A (zh)
PL (1) PL216217B1 (zh)
PT (2) PT2062914E (zh)
RU (1) RU2277539C2 (zh)
TW (1) TWI318214B (zh)
WO (1) WO2002100888A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040047846A (ko) * 2001-09-21 2004-06-05 더 어드미니스트레이터 오브 더 튜레인 에듀케이셔널 펀드 진단 또는 치료용 소마토스타틴 또는 봄베신 유사체콘쥬게이트 및 이들의 용도
AU2008200692B2 (en) * 2003-04-11 2010-07-08 Ipsen Pharma S.A.S. Eliciting a dopamine receptor agonist effect with somatostatin-dopamine chimeric analogs
BRPI0409359A (pt) 2003-04-11 2006-04-25 Sod Conseils Rech Applic análogos quiméricos de somatostatina-dopamina
WO2004093807A2 (en) * 2003-04-22 2004-11-04 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Somatostatin vectors
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
EP1874283A4 (en) * 2005-04-28 2011-11-02 Ferring Bv USE OF NEW COMPOUNDS FOR THE TREATMENT OF IBD
US9098855B2 (en) * 2006-05-23 2015-08-04 Intelligent Clearing Network, Inc. Intelligent clearing network
EP2296687A4 (en) * 2008-05-14 2012-12-26 Ipsen Pharma Sas PHARMACEUTICAL COMPOSITIONS OF SOMATOSTATIN DOPAMINE CONJUGATES
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
WO2011104627A1 (en) * 2010-02-24 2011-09-01 Ipsen Pharma S.A.S. Metabolites of dop2-d-lys(dop2)-cyclo[cys-tyr-d-trp-lys-abu-cys]-thr-nh2
WO2012142706A1 (en) * 2011-04-21 2012-10-26 Theratechnologies Inc. Growth hormone releasing factor (grf) analogs and uses thereof
UA115542C2 (uk) 2011-12-23 2017-11-27 Іпсен Мануфекчерінг Айрленд Лімітед Процес синтезу терапевтичних пептидів
US9620430B2 (en) 2012-01-23 2017-04-11 Taiwan Semiconductor Manufacturing Company, Ltd. Sawing underfill in packaging processes
TWI523863B (zh) 2012-11-01 2016-03-01 艾普森藥品公司 體抑素－多巴胺嵌合體類似物
WO2014070965A2 (en) 2012-11-01 2014-05-08 Ipsen Pharma S.A.S Somatostatin analogs and dimers thereof
AU2013355391B2 (en) * 2012-12-03 2017-08-03 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
US9096679B2 (en) 2012-12-03 2015-08-04 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
US20200157159A1 (en) 2013-04-16 2020-05-21 The Board Of Regents Of The University Of Oklahoma Peptide compounds and compositions thereof
US10266579B2 (en) 2014-09-14 2019-04-23 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic somatostatin receptor ligands
US9657020B2 (en) 2015-01-20 2017-05-23 Xoc Pharmaceuticals, Inc. Ergoline compounds and uses thereof
MX2017009406A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo isoergolina y usos de estos.
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
WO2023225043A1 (en) * 2022-05-18 2023-11-23 Kuleon Llc Tricyclic and tetracyclic serotonin receptor modulators and methods of making and using the same

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE140044C (zh)
US2619488A (en) * 1952-11-25 Method of preparing d
US2589978A (en) * 1952-03-18 Lysergyl and isolysergyl glycines
NL278401A (zh) * 1961-05-29
AT258479B (de) * 1961-05-29 1967-11-27 Farmaceutici Italia Verfahren zur Herstellung von neuen Verbindungen aus der Klasse des D-6-Methyl- (und -1,6-Dimethyl)-8-amino-methyl-ergolins I
US3966941A (en) * 1970-09-23 1976-06-29 Spofa United Pharmaceutical Works Composition for preventing lactation or pregnancy in mammals and the method for using the same
US3901894A (en) * 1974-06-06 1975-08-26 Lilly Co Eli 8-thiomethylergolines
US4291022A (en) 1975-03-11 1981-09-22 Sandoz Ltd. Organic compounds
HU172479B (hu) * 1976-03-09 1978-09-28 Gyogyszerkutato Intezet Sposob poluchenija novykh soedinenij s ehrgolenovymi i
US4133782A (en) 1976-06-07 1979-01-09 The Salk Institute For Biological Studies Somatostatin analogs with dissociated biological activities
US4190575A (en) 1977-12-27 1980-02-26 American Home Products Corporation Polypeptides related to somatostatin
IE47421B1 (en) 1977-06-08 1984-03-07 Merck & Co Inc Somatostatin analogs,process for their preparation and pharmaceutical compositions containing them
US4357259A (en) 1977-08-01 1982-11-02 Northwestern University Method of incorporating water-soluble heat-sensitive therapeutic agents in albumin microspheres
US4211693A (en) 1977-09-20 1980-07-08 The Salk Institute For Biological Studies Peptides with para-substituted phenylalanine
LU78191A1 (de) 1977-09-28 1979-05-25 Ciba Geigy Ag Verfahren zur herstellung von neuen cyclopeptiden
US4166182A (en) 1978-02-08 1979-08-28 Eli Lilly And Company 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds
CA1107273A (en) 1978-05-19 1981-08-18 Chester A. Meyers Somatostatin analogs having a substituted tryptophyl residue in position eight
JPS5819669B2 (ja) 1978-10-28 1983-04-19 白井松新薬株式会社 新規生理活性ペプチド化合物及びその製造法
DD140044A1 (de) * 1978-11-08 1980-02-06 Guenter Losse Verfahren zur herstellung von lysergyl-enkephalin-derivaten
US4215039A (en) 1979-02-15 1980-07-29 American Home Products Corporation Somatostatin analogues
US4190648A (en) 1979-03-13 1980-02-26 Merck & Co., Inc. Peptides having somatostatin activity
US4316890A (en) 1979-03-16 1982-02-23 Ciba-Geigy Corporation Peptides and processes for the manufacture thereof
US4209426A (en) 1979-05-29 1980-06-24 American Home Products Corporation Polypeptides related to somatostatin
US4328214A (en) 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
US4310518A (en) 1979-10-31 1982-01-12 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4235886A (en) 1979-10-31 1980-11-25 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
EP0029579B1 (en) 1979-11-27 1983-02-16 Sandoz Ag Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
US4369179A (en) 1979-12-14 1983-01-18 Ciba-Geigy Corporation Acylpeptides
EP0031303A3 (de) 1979-12-21 1981-11-04 Ciba-Geigy Ag Cyclooctapeptide und pharmazeutische Präparate davon, sowie Verfahren zur Herstellung derselben und ihre Anwendung
US4282143A (en) 1980-06-13 1981-08-04 American Home Products Corporation Octapeptides lowering growth hormone
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
DK81082A (da) 1981-03-06 1982-09-07 Sandoz Ag Fremgangsmaade til fremstilling af polypeptider
US4360516A (en) 1981-04-13 1982-11-23 Merck & Co., Inc. Modified D-retro cyclic hexapeptide somatostatin analogs
GB2103603B (en) * 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB2112382B (en) 1981-11-06 1985-03-06 Erba Farmitalia Ergoline derivatives
EP0083305B1 (de) 1981-12-24 1985-07-10 Ciba-Geigy Ag Cyclische Octapeptide und pharmazeutische Präparate davon, sowie Verfahren zur Herstellung derselben und ihre Anwendung
FR2522655B1 (fr) 1982-03-05 1987-03-06 Sanofi Sa Analogues de la somatostatine possedant une liaison du type hydrazide et medicaments en contenant
PH21123A (en) 1983-04-28 1987-07-27 Erba Farmitalia Ergoline derivatives
US4486415A (en) 1983-08-15 1984-12-04 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4485101A (en) 1983-10-11 1984-11-27 Administrators Of The Tulane Educational Fund Peptides
US4522813A (en) 1983-10-27 1985-06-11 Merck & Co., Inc. Cyclic hexapeptide somatostatin analogs
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
HUT42101A (en) 1985-01-07 1987-06-29 Sandoz Ag Process for preparing stomatostatine derivatives and pharmaceutical compositions containing such compounds
US4725577A (en) 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US4650787A (en) 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4585755A (en) 1985-04-29 1986-04-29 Merck & Co., Inc. Cyclic and bridged cyclic somatostatin analogs useful as local anti-inflammatory agents
US4904642A (en) * 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
HU906340D0 (en) 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
US4871717A (en) 1987-01-07 1989-10-03 Administrators Of The Tulane Educational Fund Peptides
DE3822557C2 (de) * 1987-07-10 1998-07-02 Ciba Geigy Ag Arzneimittel, enthaltend Somatostatine
EP0397779A1 (en) 1988-02-01 1990-11-22 The Upjohn Company Renin inhibiting peptides with polar end groups
GB8813339D0 (en) * 1988-06-06 1988-07-13 Sandoz Ltd Improvements in/relating to organic compounds
NO893088L (no) 1988-08-18 1990-02-19 Syntex Inc Fremgangsmaate for fremstilling av terapeutisk virksomme somatostatinlignende cykliske peptidforbindelser.
CA2012115C (en) 1989-03-15 2001-07-03 Biomeasure, Inc. Iodinated somatostatins
CA2053250A1 (en) 1989-04-26 1990-10-27 David H. Coy Linear somatostatin analogs
US5621133A (en) * 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
HU203549B (en) 1989-06-27 1991-08-28 Richter Gedeon Vegyeszet New stereoselektive hydrogenating process for producing dihydro-lisergol
JP2925321B2 (ja) 1989-12-08 1999-07-28 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド ６位にスレオニンを有するソマトスタチン類縁体オクタペプチド
US5411966A (en) * 1990-01-15 1995-05-02 Schering Aktiengesellschaft 2, 13-disubstituted ergolines, their production and use in pharmaceutical agents
EP0464178B1 (en) 1990-01-25 1995-12-06 PHARMACIA S.p.A. Process for preparing ergoline derivatives
US5043341A (en) * 1990-04-11 1991-08-27 Eli Lilly And Company N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
WO1992000986A1 (en) * 1990-07-10 1992-01-23 Neurogenetic Corporation Nucleic acid sequences encoding a human dopamine d1 receptor
HU207104B (en) 1991-01-25 1993-03-01 Biosignal Kutato Fejlesztoe Kf Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds
WO1994004752A1 (en) 1992-08-20 1994-03-03 Industrial Progress, Inc. Acid-to-alkaline papermaking process
AU669597B2 (en) * 1992-12-24 1996-06-13 Pharmacia & Upjohn S.P.A. Serotoninergic ergoline derivatives
FR2699923B1 (fr) 1992-12-28 1995-03-17 Great Lakes Chemical France Copolymères d'esters gras insaturés, leur utilisation comme additif de viscosité et huile lubrifiante contenant lesdits copolymères.
WO1994017104A1 (en) * 1993-01-21 1994-08-04 The University Of Georgia Research Foundation, Inc. Vaccines and methods for preventing and treating fescue toxicosis in herbivores
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
WO1997033550A2 (en) * 1996-03-15 1997-09-18 Start Technology Partnership Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression
US5925618A (en) * 1997-03-06 1999-07-20 American Cyanamid Company Peptides useful as somatostatin antagonists
GB9711043D0 (en) * 1997-05-29 1997-07-23 Ciba Geigy Ag Organic compounds
DE19832191A1 (de) 1998-07-17 2000-01-27 Knoell Hans Forschung Ev Neuartige Ergolinamin-Derivate und ihre Verwendung

Also Published As

Publication number Publication date
KR100620435B1 (ko) 2006-09-12
WO2002100888A1 (en) 2002-12-19
EP2062914A2 (en) 2009-05-27
CZ20033122A3 (cs) 2004-05-12
US8324386B2 (en) 2012-12-04
EP1401863A1 (en) 2004-03-31
CN1514843A (zh) 2004-07-21
JP3996897B2 (ja) 2007-10-24
IL201310A (en) 2012-06-28
JP2005503357A (ja) 2005-02-03
HUP0400245A3 (en) 2012-09-28
RU2277539C2 (ru) 2006-06-10
JP4181203B2 (ja) 2008-11-12
EP1401863B1 (en) 2009-03-04
KR100754917B1 (ko) 2007-09-04
DK2062914T3 (da) 2014-07-14
ES2483722T3 (es) 2014-08-07
CA2449634C (en) 2011-08-02
KR20050118740A (ko) 2005-12-19
AU2002305845B2 (en) 2006-03-30
US20040209798A1 (en) 2004-10-21
RU2004100109A (ru) 2005-06-27
CA2449634A1 (en) 2002-12-19
IL158922A0 (en) 2004-05-12
PT2062914E (pt) 2014-07-18
CN101481405A (zh) 2009-07-15
EP2062914B1 (en) 2014-05-07
KR100743212B1 (ko) 2007-07-26
KR20040004699A (ko) 2004-01-13
DK1401863T3 (da) 2009-05-25
US7579435B2 (en) 2009-08-25
NO332042B1 (no) 2012-06-11
US20090275501A1 (en) 2009-11-05
KR20060090842A (ko) 2006-08-16
ATE424414T1 (de) 2009-03-15
US7572883B2 (en) 2009-08-11
US8178651B2 (en) 2012-05-15
US20060211607A1 (en) 2006-09-21
AR037226A1 (es) 2004-11-03
BR0210915A (pt) 2004-06-08
ES2325880T3 (es) 2009-09-23
NO20035358D0 (no) 2003-12-02
MXPA03011321A (es) 2004-12-06
EP2062914A3 (en) 2009-08-05
NO338459B1 (no) 2016-08-15
PL364457A1 (en) 2004-12-13
PL216217B1 (pl) 2014-03-31
CZ305160B6 (cs) 2015-05-27
HK1060360A1 (en) 2004-08-06
HUP0400245A2 (hu) 2004-08-30
NZ530007A (en) 2006-02-24
JP2007224033A (ja) 2007-09-06
US20100179304A1 (en) 2010-07-15
NO20111165L (no) 2004-01-28
EP1401863A4 (en) 2006-04-26
DE60231403D1 (de) 2009-04-16
PT1401863E (pt) 2009-07-23

Similar Documents

Publication Publication Date Title
TWI318214B (en) Somatosatin-dopamine chimeric analogs
EP1385538A4 (en) CHIMERIC VACCINES
AU2002349297A8 (en) Statin-like compounds
GB0101996D0 (en) Organtic compounds
IL170742A0 (en) Somatostatin-dopamine chimeric analogs
GB0112324D0 (en) Compounds
GB0102668D0 (en) Compounds
AU2002360487A8 (en) Acyclovir-peptide analogs
GB0108102D0 (en) Compounds
GB0102673D0 (en) Compounds
GB0102665D0 (en) Compounds
EP1458669A4 (en) ACTIVE COMPOUNDS ON THE NEUROLOGICAL PLAN
GB0118364D0 (en) Compounds
GB0115178D0 (en) Compounds
GB0108097D0 (en) Compounds
GB0105098D0 (en) Compounds
GB0104396D0 (en) Compounds
GB0111183D0 (en) Compounds
GB0104397D0 (en) Compounds
GB0104398D0 (en) Compounds
GB0104399D0 (en) Compounds
GB0104401D0 (en) Compounds
GB0103314D0 (en) Compounds
GB0105737D0 (en) Compounds
GB0106673D0 (en) Compounds

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees